Notwithstanding new pharmacological and non-pharmacological approaches, such as optimising care using new monitoring strategies,[1,2] heart failure (HF) remains a huge public health problem worldwide with increased morbidity and mortality [3,4]. Moreover, HF is associated to impaired health-related quality of life (QoL) and high healthcare costs, mainly due to hospital admissions [5–8]. Therefore, prevention-targeted and integrated disease management approaches focused on the early post-discharge period, the so-called ‘vulnerable phase’, where a higher proportion of events in HF patients are concentrated, have been assessed and deployed in recent years [9–11].
